Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.

The prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned development of RG6206, a myostatin inhibitor. The Swiss group revealed the ...

have recently been testing myostatin inhibitors in phase three trials in patients with spinal muscular atrophy, or SMA, a ...

Myostatin inhibitors meanwhile have had a patchy history in drug development to date. Early experiments with these drugs suggested that while they can increase muscle mass, that may not lead to ...

Companies like Eli Lilly, Regeneron Pharmaceuticals, and Scholar Rock are attempting to prevent this muscle loss through the therapeutic inhibition of myostatin using antibodies and other methods.